<DOC>
	<DOCNO>NCT00144573</DOCNO>
	<brief_summary>This open-label , clinical pharmacology study evaluate safety PK MRA patient RA Renal Impairment .</brief_summary>
	<brief_title>Clinical Pharmacology Study MRA Patient With Rheumatoid Arthritis ( RA ) With Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion criterion Patients diagnose RA accord 1987 ACR ( American College Rheumatology ) classification criterion Patients RA least 6 month prior enrollment Patients creatinine clearance le 10 mL/min high 80 mL/min Exclusion criterion Patients Class IV Steinbrocker functional impairment enrollment Patients undergoing dialysis Patients treat underlying disease biological agent , infliximab etanercept , receive treatment leflunomide , within 12 week treatment investigational product</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>